Investigative Ophthalmology & Visual Science Cover Image for Volume 65, Issue 7
June 2024
Volume 65, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2024
Novel Oguchi Disease Mechanism
Author Affiliations & Notes
  • Ching-Kang Jason Chen
    Molecular Medicine, The University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States
    Ophthalmology, The University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States
  • Yu-Jiun Chen
    Molecular Medicine, The University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States
  • Amber Adair Lewis
    Molecular Medicine, The University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States
  • Frank Sungping Chen
    Otolaryngology, PeaceHealth Medical Group, Eugene, Oregon, United States
  • Footnotes
    Commercial Relationships   Ching-Kang Chen None; Yu-Jiun Chen None; Amber Lewis None; Frank Chen None
  • Footnotes
    Support  NIH Grants EY013811, EY032898, EY034219
Investigative Ophthalmology & Visual Science June 2024, Vol.65, 6199. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Ching-Kang Jason Chen, Yu-Jiun Chen, Amber Adair Lewis, Frank Sungping Chen; Novel Oguchi Disease Mechanism. Invest. Ophthalmol. Vis. Sci. 2024;65(7):6199.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Timely deactivation of photoexcited visual pigment is essential for normal vision and failing to do so causes night blindness and photoreceptor degeneration. The G protein-coupled receptor kinase 1 (GRK1) is the enzyme responsible for phosphorylating visual pigments in rod and cone and its loss-of-function mutations are found in many human Oguchi disease patients. It is widely thought that truncated or mutant GRK1 loses its catalytic activity toward visual pigments, however, we present here a novel disease-causing mechanism in that the V380D mutation of GRK1 leads to protein instability in photoreceptors.

Methods : We generated a transgenic mouse line where expression of a V380D mutant bovine Grk1 cDNA is put under the control of a mouse rhodopsin promoter. We mated the mice into the wild type (WT) and Grk1 knockout (-/-) backgrounds. We also generated a V380D knock-in mouse line by CRISPR/Cas9-based gene editing. Phospho-specific GRK1 antibody recognizing its autophosphorylation sites was made and validated, as well as several phospho-specific rhodopsin antibodies recognizing specific phosphorylated Serine residues at its C-terminal tail. Immunohistochemistry was then used to characterize the catalytic activity of WT and V380D mutant GRK1 in different genetic backgrounds using these phospho-specific antibodies.

Results : Transgenic overexpression of the mutant Grk1 is readily detectable by RT-PCR, but it does not elevate the total GRK1 level judged by Western Blot. When mated to the Grk1 knockout background, transgenic V380D GRK1 protein becomes detectable at a ~20% WT level. Surprisingly, the transgenic V380D GRK1 retains some catalytic activity toward its own authophosphorylation sites and toward rhodopsin’s C-terminal substrate sites. On the contrary, the mutant V380D protein is hardly detected in the homozygous V380D knock-in mouse retinas and as a result, light-dependent rhodopsin phosphorylation does not occur, mimicking the pathophysiology of human Oguchi disease by failing to deactivate photoexcited rhodopsin in a timely manner.

Conclusions : Our data suggests that protein instability, rather than a lack of catalytic activity, is the disease-causing mechanism underlying human Oguchi disease involving the Grk1 V380D mutations.

This abstract was presented at the 2024 ARVO Annual Meeting, held in Seattle, WA, May 5-9, 2024.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×